Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 1/20 | 0.44 |
| ▸ | PROKR1 | Q8TCW9 | 7/20 | 0.42 |
| ▸ | PROKR2 | Q8NFJ6 | 2/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 2/20 | 0.40 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14471146 | 0.87 | PDE1B (0.42) | PDE1BPROKR1PROKR2P2RX3MAPT | |
| SCHEMBL4769739 | 0.82 | PROKR1 (0.60) | PROKR1PROKR2 | |
| SCHEMBL10278617 | 0.81 | BACE1 (0.47) | PROKR1PROKR2APPBACE1MAPT | |
| SCHEMBL19906485 | 0.79 | MAPT (0.46) | PROKR1PROKR2P2RX3MAPTTHRB | |
| SCHEMBL14037825 | 0.78 | MAPT (0.43) | PROKR1PROKR2APPBACE1MAPT | |
| SCHEMBL319694 | 0.75 | PROKR1 (0.53) | PROKR1PROKR2P2RX3MAPTTHRB | |
| SCHEMBL19906491 | 0.74 | RXFP1 (0.41) | PDE1BPROKR1PROKR2P2RX3MAPT | |
| SCHEMBL326654 | 0.74 | MAPT (0.41) | PROKR1PROKR2P2RX3MAPTTHRB | |
| SCHEMBL22630794 | 0.73 | P2RX3 (0.48) | PROKR1PROKR2P2RX3 | |
| SCHEMBL2635865 | 0.72 | PROKR1 (0.45) | PROKR1PROKR2P2RX3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385042-B1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-25 | — | — | EP | disclosed |
| EP-2385042-B1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-25 | — | — | EP | disclosed |
| EP-2585069-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | Janssen Pharmaceutica, N.V. (BE) | 2013-05-01 | — | — | EP | disclosed |
| EP-1973886-B1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-27 | — | — | EP | disclosed |
| US-8372973-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-12 | — | — | US | disclosed |
| US-8372973-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-12 | — | — | US | disclosed |
| US-8372973-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-12 | — | — | US | disclosed |
| US-20120028997-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | COATS STEVEN J (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028997-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | COATS STEVEN J (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028997-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | COATS STEVEN J (US) | 2012-02-02 | — | — | US | disclosed |
| US-7902358-B2 | Gastrointestinal disorders; inflammatory bowel disorders; gastroesophageal reflux, constipation; diarrhea | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-08 | — | — | US | disclosed |
| US-7902358-B2 | Gastrointestinal disorders; inflammatory bowel disorders; gastroesophageal reflux, constipation; diarrhea | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-08 | — | — | US | disclosed |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | disclosed |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | US | disclosed |
| EP-1976528-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-08 | — | — | EP | disclosed |
| EP-1973886-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007079214-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079163-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028997-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | PROKR1, PROKR2, GIPR | PDE1B 1711/4885PROKR1 1/4885PROKR2 2/4885 |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | PROKR1, PROKR2, GIPR | PDE1B 1711/4885PROKR1 1/4885PROKR2 2/4885 |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | PROKR2, PROKR1, GIPR | PDE1B 1026/4885PROKR1 2/4885PROKR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.